Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Agile Therapeutics, Inc. - Common Stock (NQ:AGRX)

N/A UNCHANGED
Last Price Updated: 4:00 PM EDT, Mar 25, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Agile Therapeutics, Inc. - Common Stock

< Previous 1 2 Next >
Agile Therapeutics Announces Closing of $7.5 Million Public Offering
From Agile Therapeutics, Inc.
Via GlobeNewswire
Agile Therapeutics Announces Pricing of $7.5 Million Public Offering
From Agile Therapeutics, Inc.
Via GlobeNewswire
Agile Therapeutics Reports First Quarter 2023 Financial Results And Provides Corporate Update
From Agile Therapeutics, Inc.
Via GlobeNewswire
Agile Therapeutics: This BioPharma Firm Is Nimbly Solving Unmet Needs For Women
By Johnny Rice, Benzinga 
Via TheNewswire.com
NASDAQ: AGRX Agile Therapeutics Anticipates Increased Growth In Q3 of 2022
Matt Riley - Head of Investor Relations & Corporate Communications 
Via TheNewswire.com
Agile Therapeutics to Report First Quarter 2023 Financial Results and Provide Business Update on Thursday, May 11, 2023
Live Conference Call and Webcast at 4:30 p.m. ET 
From Agile Therapeutics, Inc.
Via GlobeNewswire
Agile Therapeutics Announces Preliminary Expectations for First Quarter 2023
From Agile Therapeutics, Inc.
Via GlobeNewswire
Agile Therapeutics Regains Compliance With Nasdaq Minimum Bid Price Requirement
From Agile Therapeutics, Inc.
Via GlobeNewswire
Proprietary Transdermal Advancements for Easier, Non-Daily Contraception Options in Women: Agile Therapeutics (NASDAQ: AGRX)
Via Get News
Agile Therapeutics Announces 1-For-50 Reverse Stock Split
From Agile Therapeutics, Inc.
Via GlobeNewswire
Agile Therapeutics Reports Fourth Quarter & Full Year 2022 Financial Results and Provides Corporate Update
From Agile Therapeutics, Inc.
Via GlobeNewswire
Agile Therapeutics to Report Fourth Quarter and Full Year 2022 Financial Results and Provide Business Update on Wednesday, March 22, 2023
Live Conference Call and Webcast at 4:30 p.m. ET 
From Agile Therapeutics, Inc.
Via GlobeNewswire
Agile Therapeutics Granted 180-Day Extension by Nasdaq to Meet the Minimum Bid Price Requirement
From Agile Therapeutics, Inc.
Via GlobeNewswire
Agile Therapeutics Provides Clinical Update on Twirla and Status of Pipeline Evaluation
From Agile Therapeutics, Inc.
Via GlobeNewswire
Agile Therapeutics Announces Distribution of Series C Preferred Stock to its Holders of Common Stock
From Agile Therapeutics, Inc.
Via GlobeNewswire
Agile Therapeutics Provides Updates on 2022 Twirla Performance and 2023 Commercial Plan
From Agile Therapeutics, Inc.
Via GlobeNewswire
This Biotech Company is Pursuing Positive Cash Flow In 2023
Biotech company Agile Therapeutics Inc. (NASDAQ: AGRX) began selling its contraceptive patch in 2021, and the company is pursuing positive cash flow by the end of 2023. 
Via TheNewswire.com
Agile Therapeutics To Present At The Upcoming RHK Capital Disruptive Growth Conference
From Agile Therapeutics, Inc.
Via GlobeNewswire
Women’s Healthcare Company Agile Therapeutics Says It Believes It Has An Effective Business Plan In Place For Growth And Generating Positive Cash Flow
Agile Therapeutics Inc. (NASDAQ: AGRX) is on a journey to fulfill the unmet health needs of women with products designed to provide them with contraceptive options. 
Via TheNewswire.com
Agile Therapeutics Reports Third Quarter 2022 Financial Results and Provides Corporate Update
From Agile Therapeutics, Inc.
Via GlobeNewswire
Agile Therapeutics to Report Third Quarter 2022 Financial Results and Provide Business Update on Monday, November 7, 2022
Live Conference Call and Webcast at 4:30 p.m. ET 
From Agile Therapeutics, Inc.
Via GlobeNewswire
Can This Company’s Birth Control Patch Disrupt The Contraceptive Market?
From Evofem Biosciences Inc.’s (OTCMKTS: EVFM) Phexxi vaginal gel contraceptive to Dare Bioscience Inc.’s (NASDAQ: DARE) Ovaprene, an investigational hormone-free monthly intravaginal contraceptive,... 
Via TheNewswire.com
Agile Therapeutics Announces Reorganization of Leadership Team
From Agile Therapeutics, Inc.
Via GlobeNewswire
Agile Therapeutics to Report Second Quarter 2022 Financial Results and Provide Business Update on Thursday, August 11, 2022
Live Conference Call and Webcast at 4:30 p.m. ET 
From Agile Therapeutics, Inc.
Via GlobeNewswire
50+ Companies to Present at the Access to Giving Virtual Investor Conference on July 13th - 15th, 2021
RALEIGH, NC / ACCESSWIRE / July 8, 2021 / Access to Giving - an investor conference themed around investor education and advocacy begins next week, July 13th - 15th, 2021. More than 50 companies are... 
From Access to Giving
Via AccessWire
Women’s Healthcare Company dedicated to fulfilling the unmet health needs of today’s Modern Women: Agile Therapeutics (NASDAQ: AGRX)
Via Get News
50+ Companies to Present at the Access to Giving Virtual Investor Conference on July 13th - 15th, 2021
RALEIGH, NC / ACCESSWIRE / June 23, 2021 / Access to Giving - an investor conference themed around investor education and advocacy is set for July 13-15, 2021. There will be 50+ companies conducting... 
From Access to Giving
Via AccessWire
< Previous 1 2 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.